

REMARKS

Claims 1-51 are pending in the present application.

The Examiner has required election in the present application between:

Group I, claims 1-32 and 46, drawn to compounds of formula (I), pyrazolo[1,5-a]pyrimidines and compositions thereof;

Group II, claims 33 and 34, drawn to a process of making compounds of formula (I), pyrazolo[1,5-a]pyrimidines;

Group III, claims 35-38, drawn to a method for treating or preventing diseases associated with a GABA receptor with compounds of formula (I), pyrazolo[1,5-a]pyrimidines;

Group IV, claims 39-45 drawn to a method for treating or preventing anxiety, epilepsy, sleep disorders, sedation, including anesthesia and inducing muscle relaxation with compounds of formula (I), pyrazolo[1,5-a]pyrimidines;

Group V, claims 47-49, drawn to use of a compound of group I;

Group VI, claim 50, drawn to a process for preparing the intermediate of formula (VIII);
and

Group VII, claims 27-29, drawn to a process of preparing the intermediate of formula (VII).

The Examiner has not designated a Group for claim 51.

For the purpose of examination of the present application, Applicants elect, with traverse, Group I, Claims 1-32 and 46.


The present claims are linked as to form a single general inventive concept under PCT Rule 13.1. Moreover, the claims share a special technical feature, namely the compounds of formula (I). Since compounds of formula (I) define a contribution over the prior art, and all claims share this feature (whether by claiming the compounds *per se*, methods of making or methods of using), all claims share Unity of Invention. At the very least, claims 1-26 and 30-49 share Unity of Invention.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Marc S. Weiner, Registration No. 32,181 at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: JAN 16 2008

Respectfully submitted,

By  #42874
Marc S. Weiner
Registration No.: 32,181
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000
Attorney for Applicant